WHAT’S KNOWN?
- Autologous hematopoietic stem cell transplantation (AHSCT) was first
used as frontline, consolidative treatment for aggressive non-Hodgkin
lymphoma (NHL) in the early ‘90s.
- In selected centres, upfront AHSCT has also been considered a feasible
form of management for poor risk patients.
-There is scarce information available in regards to the survival
outcome of NHL in South East Asia regions. Reports on the outcome of
high dose therapy followed by AHSCT were mainly from developed
countries.